Group 1 - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between 46 million to 52 million yuan, representing an increase of 27.06 million to 33.06 million yuan compared to the same period last year, which is a year-on-year increase of 142.84% to 174.52% [1] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to increase by 55.80% to 86.33% [2] - The increase in profit is primarily due to an increase in operating income and an improvement in gross profit margin during the reporting period [2] Group 2 - The net profit for the same period last year was 18.94 million yuan, and the net profit after deducting non-recurring gains and losses was 19.66 million yuan [2] - The earnings per share for the same period last year was 0.09 yuan [2] - The performance forecast data is preliminary and subject to final disclosure by the company [2]

Core Viewpoint - The article discusses various convertible bonds and company share transactions, highlighting adjustments and expectations for future performance, particularly focusing on the financial outlook of Meinuohua. Group 1: Convertible Bonds - Ruida Convertible Bond is nearing a downward adjustment [1] - Caitong Convertible Bond is close to a downward adjustment [1] - Zhongzhuang Convertible Bond will not undergo a downward adjustment [1] - Libo Convertible Bond is open for subscription [1] Group 2: Share Transactions - Beilu Pharmaceutical's shareholders plan to inquire about transferring 1.49% of the company's shares [1] - Yinxin Technology's controlling shareholder's concerted action party intends to reduce holdings by no more than 1% of the company's shares [1] Group 3: Company Financial Outlook - Meinuohua expects to achieve a net profit of 46 million to 52 million in the first half of 2025, representing a year-on-year growth of 142.84% to 174.52% [1]

Key Points - Jiangnan Water received a stake increase from Lianan Life Insurance, reaching 5.03% of total shares [3] - Yingboer plans to transfer 100% equity of Zhuhai Dingyuan for 239 million yuan to optimize asset structure [4] - Chengbang Co. warns that its stock price fluctuations are not aligned with its fundamentals, as it has seen five consecutive trading days of price increases [6] - Weimais intends to invest 190 million yuan into its subsidiary for a new electric drive assembly project [7] - Fosun Pharma's subsidiary received EU GMP certification for its production facilities, indicating compliance with EU standards [8] - Jingwei Huikai plans to acquire an additional 12.44% stake in Nosi Micro, increasing its control in the semiconductor sector [9] - ST Tongmai will remove its delisting risk warning starting July 4, while continuing other risk warnings [10] - ST Modern seeks to apply for the removal of other risk warnings but will maintain delisting risk warnings [11] - Luxshare Precision is planning to issue H-shares for listing on the Hong Kong Stock Exchange [12] - Hainan Highway intends to purchase a 51% stake in Hainan Jiaokong Petrochemical, which will become a subsidiary [13] - Jucheng Co. plans to transfer 1.25% of its shares through a price inquiry [14] Performance Highlights - Foton Motor reported a 150.96% year-on-year increase in new energy vehicle sales for the first half of the year [15] - Jiangling Motors achieved a total vehicle sales of 172,700 units in the first half, up 8.15% year-on-year [16] - Changan Automobile's sales reached 1.3553 million units in the first half, with new energy vehicle sales growing by 49.05% [17] - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of the year [18] - Jihong Co. anticipates a net profit increase of 55% to 65% for the first half of the year [19] - Nanjing Business Travel expects a net profit decrease of 67.4% to 78.27% for the first half of the year [20] - Madi Technology forecasts a net profit of 25 million to 27 million yuan, marking a turnaround from losses in the previous year [21] Major Contracts - Dash Intelligent signed a contract for an intelligent project worth 11.88 million yuan [22] - Jinyi Industrial won a bid for a 335 million yuan intercity railway materials procurement project [23] - Sichuan Road and Bridge signed a construction contract worth approximately 11.596 billion yuan [24] - Fulian Precision signed a cooperation framework agreement with Chuanfa Longmang for lithium battery material projects [26] Share Buybacks - Kweichow Moutai repurchased 72,000 shares in June, totaling 1.02 billion yuan [27] - Feiwo Technology plans to repurchase shares worth 25 million to 50 million yuan [28] - Nengte Technology intends to repurchase shares worth 300 million to 500 million yuan for capital reduction [29] - CATL has repurchased 6.641 million A-shares for a total of 1.551 billion yuan [30] Shareholding Changes - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [31] - Sanwei Xinan's shareholder intends to reduce its stake by up to 2% [33] - Data Port's shareholders plan to reduce their stakes by up to 2% [34] - Zhuzhou Design's controlling shareholders plan to reduce their stakes by up to 3% [35] - Tianji Co.'s controlling shareholders plan to reduce their stakes by up to 3% [36] - Anjisi's shareholders plan to reduce their stakes by up to 4% [37] Financing Activities - CITIC Securities received approval to issue up to 20 billion yuan in perpetual subordinated bonds [39]

Group 1 - Guizhou Moutai has repurchased a total of 3.3821 million shares as of June 30, 2025, accounting for 0.2692% of the total share capital, with a total expenditure of 5.202 billion yuan [2] - Luxshare Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global financing capabilities and governance transparency [2] - Huazhong Xinchuang has received a project notification from a leading domestic eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [3] Group 2 - Meinohua expects a net profit of 46 million to 52 million yuan for the first half of 2025, representing a year-on-year increase of 142.84% to 174.52% [4] - Jiangnan Water has received a report from shareholder Lianan Life Insurance indicating an increase in shareholding by 46.99 million shares, representing 5.03% of the total share capital [5] - Huasen Pharmaceutical has received approval for clinical trials of its CX001 sustained-release tablets, marking a milestone for its innovative drug development platform [6] Group 3 - Zongshen Power anticipates a net profit growth of 70% to 100% for the first half of the year [7] - Yutong Bus reported a sales volume of 5,919 units in June, a year-on-year increase of 24.79% [7] - Guangzhou Port expects a 7.0% year-on-year increase in container throughput for June 2025 [7] Group 4 - Data Port's shareholders plan to reduce their holdings by up to 1.74% and 0.26% of the company's shares [9] - Humanwell Healthcare's shareholder plans to increase its stake by 1% to 2% [9] - Nengte Technology plans to repurchase shares worth between 300 million to 500 million yuan [10]

Core Viewpoint - Meinuo's net profit for the first half of the year is expected to increase by 142.84% to 174.52%, amounting to between 46 million to 52 million yuan, driven by increased revenue and improved gross margins [1] Group 1: Financial Performance - The company's net profit growth, excluding non-recurring items, is projected to be between 55.80% and 86.33% [1] - In Q1, Meinuo reported revenue of 276 million yuan, a year-on-year increase of 5.22%, with a net profit of 21.22 million yuan, up 51.12% [1] - The expected profit range for the first half of the year is only slightly above the same period in 2018, indicating a recovery and release of performance after two years of decline [1] Group 2: Industry Context - During the public health crisis, global raw material shortages led to an expansion of raw material drug production capacity, resulting in many new but unprofitable companies entering the market [2] - Meinuo's management believes that the raw material drug sector will see a "survival of the fittest" scenario, with stronger companies emerging post-competition [2] - The industry is expected to recover by 2025, with stable prices for key products and some intermediate products experiencing price increases [2] Group 3: Future Outlook - Institutions predict Meinuo's 2025 revenue to reach 1.653 billion yuan, a year-on-year increase of 20.43%, and net profit to be 152 million yuan, up 127.75% [3] - Since May, Meinuo's stock price has risen by 54%, with a recent surge attributed to performance recovery and advancements in the JH389 project for obesity treatment [3] - The company has signed a strategic cooperation agreement with the University of Michigan for the JH389 project, which has shown promising data in animal models [3]

Corporate Announcements - Jiangnan Water received a stake increase from Lian'an Life, reaching 5.03% of total shares [3] - Yingboer plans to transfer 100% equity of Zhuhai Dingyuan for 239 million yuan to optimize asset structure [4] - Chengbang Co. experienced a five-day stock price surge, diverging from its fundamentals, with a warning about market risks [5] - Weimais intends to invest 190 million yuan in its subsidiary for a new electric drive assembly project, expected to take 12 months [6] - Fosun Pharma's subsidiary received EU GMP certification for its production facilities, marking a significant compliance achievement [7] Performance Highlights - Foton Motor reported a 150.96% year-on-year increase in new energy vehicle sales for the first half of the year, totaling 50,142 units [9] - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of 2025, driven by revenue growth and improved gross margins [10] - Madi Technology anticipates a net profit of 25 to 27 million yuan for the first half of 2025, marking a turnaround from a loss of 76.33 million yuan in the previous year [11] Major Contracts - Dash Intelligent signed a contract for an intelligent project worth 11.88 million yuan, representing 0.37% of its 2024 revenue [13] - Jinyi Industrial won a bid for a 335 million yuan materials procurement project for the Nanjing-Huaian intercity railway [14] Share Buybacks - Kweichow Moutai repurchased 72,000 shares in June, totaling 1.02 billion yuan, with a cumulative buyback of 3.38 million shares amounting to 5.202 billion yuan [16] - Feiwo Technology plans to repurchase shares worth 25 to 50 million yuan for equity incentives, with a maximum price of 43.44 yuan per share [17] Shareholding Changes - Renfu Pharmaceutical's shareholder,招商生科, plans to increase its stake by 1% to 2% within six months, with a price cap of 25.53 yuan per share [19] Financing Activities - CITIC Securities received approval to issue up to 20 billion yuan in perpetual subordinated bonds [21]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-086 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 2025 年 1 月 1 日至 2025 年 6 月 30 日。 2025 年半年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 宁波美诺华药业股份有限公司（以下简称"公司"）2025 年半年度实现 归属于母公司所有者的净利润预计为 4,600.00 万元到 5,200.00 万元,与上年同 期相比增加 2,705.75 万元到 3,305.75 万元，同比增加 142.84%到 174.52%。 扣除非经常性损益事项后，归属于母公司所有者的净利润预计为 3,062.52 万元到 3,662.52 万元,同比增加 1,096.89 万元到 1,696.89 万元，同 比增加 55.80%到 86.33%。 一 ...

金十数据7月2日讯，美诺华公告，公司2025年半年度实现归属于母公司所有者的净利润预计为4600万元 到5200万元,与上年同期相比增加2705.75万元到3305.75万元，同比增加142.84%到174.52%。扣除非经常 性损益事项后，归属于母公司所有者的净利润预计为3062.52万元到3662.52万元,同比增加1096.89万元到 1696.89万元，同比增加55.80%到86.33%。 美诺华：预计2025年上半年净利润同比增长142.84%-174.52% ...

Summary of Menohua's Conference Call Company Overview - **Company**: Menohua - **Industry**: Biotechnology, specifically focusing on probiotics and health products Key Points and Arguments G389 Project Development - Menohua has innovatively utilized genetically edited probiotics (such as lactic acid bacteria) to efficiently express GLP-1 analog G389, which is expected to be used for glucose reduction and fat loss [2][5] - The G389 project has completed animal testing and is collaborating with an Italian probiotic company for European registration, with a patent application submitted [2][6] - The commercialization plan for G389 includes two paths: registering it as a non-drug product with the Italian partner, expected to launch in 2026, and using it as a food additive across various products [2][9] Market Potential and Strategy - Menohua aims to cover 10% of the rebound population from GLP-1 drug usage, targeting approximately 750,000 individuals, with a potential market size of 5 billion RMB [3][15] - The company is cautiously optimistic about the market potential, focusing on technology and registration [3][15] - In the U.S. market, Menohua plans to register G389 as a formula and then as a new food ingredient, with a strategy to ensure compliance by registering it as a genetically modified food [13][14] Collaboration with Italian Partner - The Italian partner is a well-established probiotic company with annual sales of around 200 million euros, providing Menohua with necessary expertise and market access [11][10] - The collaboration includes technical exchanges, production process optimization, and market promotion strategies [10][11] Competitive Advantages - Menohua's core competitive barriers include patent protection and technical design, making it difficult for competitors to enter the market [19] - The unique expression of sufficient and effective GLP-1 analogs through probiotics presents a significant challenge for potential competitors [19] Financial Performance and Future Outlook - In the first half of 2025, Menohua reported good overall performance despite a 20% year-on-year decline in API prices, with significant growth in new products and contract manufacturing [23] - The company expects to achieve a net profit margin of 8%-10% and good revenue growth for the year [23] - Menohua anticipates a dual growth in revenue and profit in 2025, with a breakthrough phase starting in 2026 [27][28] Future Product Development - Besides G389, Menohua plans to develop new products such as hangover relief probiotics and anti-inflammatory targets, aiming for differentiation in the market [21][28] - The company is exploring new directions in health and innovative drugs to achieve rapid returns for shareholders [28] Regulatory and Market Entry Strategies - Menohua is considering entering the domestic market through cross-border e-commerce, with plans for compliance and registration in the future [26] - The strategy for non-drug product launches focuses on technical development and finding partners for commercialization [26] Conclusion - Menohua is positioned to leverage its innovative G389 project and strategic partnerships to capture market opportunities in the probiotic and health product sectors, with a focus on compliance, safety, and effective commercialization strategies [2][3][11][27]

Core Viewpoint - The announcement details the results of the stock option and restricted stock incentive plan for the second quarter of 2025, indicating no shares were exercised during this period. Summary by Sections Stock Option Exercise Results - The total number of stock options available for exercise in the third exercise period of the 2021 stock option and restricted stock incentive plan is 1,976,997 shares, with the exercise start date on January 17, 2025. As of June 30, 2025, no shares have been exercised, representing 0% of the total available for this period [1][12]. - For the reserved stock options in the second exercise period, the total available is 738,491 shares, with the exercise start date on December 25, 2024. Similarly, no shares have been exercised as of June 30, 2025, also representing 0% of the total available [1][12]. Decision-Making Process and Disclosure - The decision-making process for the stock option exercise involved independent directors providing consent and avoiding conflicts of interest during the voting on related proposals [2][3]. Stock Option and Restricted Stock Plan Adjustments - The number of incentive participants was adjusted from 327 to 302 due to 25 participants voluntarily giving up their participation. The total number of stock options remains at 3,865,060, with a grant price of 32.26 CNY per option and restricted stock at 16.13 CNY per share [6][7]. Stock Listing and Trading Arrangements - The stock options from the third exercise period and the reserved options from the second exercise period will be exercised through a self-exercise method, with shares listed for trading on the second trading day after the exercise date [11][12]. Impact on Financial Reports - The exercise of stock options is not expected to have a significant impact on the company's financial condition or operating results [14].